Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people do regain a significant proportion of lost weight after stopping semaglutide. Clinical trial data show that, on average, participants who discontinued the medicine regained around two-thirds of the weight they had lost within a year of stopping — even when they continued lifestyle changes. That is not a failure of willpower. Semaglutide works by altering the hormonal signals that govern hunger and fullness; when the medicine leaves your system, those signals return to their pre-treatment pattern. These are prescription-only medicines, and any decision about stopping or continuing is one a prescriber should make with you based on your full clinical picture.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Semaglutide reduces appetite and slows gastric emptying by activating GLP-1 receptors in the gut and brain. That combination makes eating less feel manageable, often dramatically so. But obesity is a chronic condition with strong biological drivers, and the brain's hunger-regulation circuitry does not permanently reset during treatment. Once semaglutide clears your system (it has a roughly one-week half-life, so it takes several weeks to fully wash out), those circuits revert. Hunger signals intensify again, fullness arrives later, and energy intake tends to rise toward pre-treatment levels.
This is why researchers and clinicians increasingly describe GLP-1 medicines as working in the same way as treatment for other chronic conditions, blood pressure medication, for instance. Stopping the medicine does not mean the underlying condition has resolved. The NHS medicines information for semaglutide notes that it is a long-term treatment for weight management, not a short course.
The question of whether everyone regains weight is explored in more detail at our page on that specific question, but the short answer is: the majority do to some degree, though the rate and amount varies.
The clearest evidence comes from the STEP 4 trial, a study in which participants who had lost weight on semaglutide 2.4 mg were then randomised either to continue or to switch to placebo. Those who switched to placebo regained around 6.9% of their body weight (roughly two-thirds of what they had originally lost) over the following 48 weeks, while the group who stayed on treatment continued to lose weight.
The same pattern appeared after the STEP 1 trial's treatment period ended: the original STEP 1 paper in the New England Journal of Medicine found ~15% average weight loss at 68 weeks; follow-up data showed substantial regain after stopping. Similar findings have been replicated across the GLP-1 literature, including for tirzepatide.
It is worth being honest about the numbers: some regain happens quickly, within the first few months. Others maintain more of their loss for longer, particularly if they have built durable habits around eating and activity during treatment. But the hormonal reset tends to win out over time without ongoing intervention.
For context on long-term cost and planning, our Wegovy cost and pricing page covers what private treatment typically involves financially over different time horizons.
There is no guaranteed method, but the evidence points toward several factors that reduce regain. Sustained muscle mass matters: people who incorporated resistance exercise during treatment retain more metabolically active tissue, which helps regulate weight over time. Dietary habits built during treatment (specifically higher protein intake and stable eating patterns) also appear protective. Importantly, the speed of stopping may matter too; some prescribers taper the dose rather than ceasing abruptly, though evidence specifically on tapering strategies is still emerging.
Planning the transition well in advance of stopping is sensible. If you know a break is coming (before a holiday, around a busy period at work, or simply because you want to pause) a prescriber can help you build a plan. That conversation is more useful six weeks before stopping than the week after.
Some people who regain weight after stopping go on to restart treatment. Semaglutide can be used again following a break, subject to clinical assessment. The detail on weight changes when stopping Wegovy covers what typically happens in the first weeks and months. Our page on gaining weight after stopping Wegovy also addresses what to do once regain has already started.
Talk to your prescriber before stopping, not after. That is the single most useful step. They can review whether you have reached a point of sufficient benefit, whether a dose reduction rather than cessation makes sense, and what follow-up monitoring is appropriate.
For people on treatment through a regulated online pharmacy (where there is no automatic repeat, and every order involves fresh clinical review) this conversation is built into the process. At nume, a GPhC-registered prescriber personally reviews each case; if your circumstances have changed, that review is the right moment to raise stopping or pausing.
You can also read about whether weight comes back after stopping Wegovy specifically, or explore how Wegovy works as a treatment more broadly. If you are weighing up whether to start or restart, starting a free consultation is the first step, a prescriber will assess your full history, not just your BMI.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.